Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AMS NASDAQ:BOLT CNSX:TN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.44-0.4%$2.51$2.27▼$3.59$15.88M0.3112,105 shs2,419 shsBOLTBolt Biotherapeutics$5.55+3.9%$5.45$4.59▼$14.36$10.66M0.914,814 shs9,555 shsTNTartisan Nickel$0.00$0.00▼$0.00N/AN/AN/AN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services-3.16%+1.24%+0.41%+1.24%-8.58%BOLTBolt Biotherapeutics+2.10%+1.14%+3.69%-4.47%-56.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMSAmerican Shared Hospital Services$2.44-0.4%$2.51$2.27▼$3.59$15.88M0.3112,105 shs2,419 shsBOLTBolt Biotherapeutics$5.55+3.9%$5.45$4.59▼$14.36$10.66M0.914,814 shs9,555 shsTNTartisan Nickel$0.00$0.00▼$0.00N/AN/AN/AN/A10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMSAmerican Shared Hospital Services-3.16%+1.24%+0.41%+1.24%-8.58%BOLTBolt Biotherapeutics+2.10%+1.14%+3.69%-4.47%-56.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMSAmerican Shared Hospital Services 0.00N/AN/AN/ABOLTBolt Biotherapeutics 2.33Hold$47.50782.90% UpsideTNTartisan Nickel 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TN, AMS, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025BOLTBolt BiotherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMSAmerican Shared Hospital Services$28.34M0.56$0.86 per share2.85$4.68 per share0.52BOLTBolt Biotherapeutics$7.69M1.34N/AN/A$29.89 per share0.18TNTartisan NickelN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMSAmerican Shared Hospital Services$2.19M$0.60N/A8.13N/A-8.27%-8.07%-3.87%11/12/2025 (Estimated)BOLTBolt Biotherapeutics-$63.12M-$26.66N/AN/AN/AN/A-91.67%-53.19%11/11/2025 (Estimated)TNTartisan NickelN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TN, AMS, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BOLTBolt Biotherapeutics-$6.40-$4.46+$1.94-$4.46$0.82 million$1.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMSAmerican Shared Hospital ServicesN/AN/AN/AN/AN/ABOLTBolt BiotherapeuticsN/AN/AN/AN/AN/ATNTartisan NickelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMSAmerican Shared Hospital Services0.321.171.17BOLTBolt Biotherapeutics0.563.113.11TNTartisan NickelN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMSAmerican Shared Hospital Services23.16%BOLTBolt Biotherapeutics86.70%TNTartisan NickelN/AInsider OwnershipCompanyInsider OwnershipAMSAmerican Shared Hospital Services23.80%BOLTBolt Biotherapeutics30.90%TNTartisan NickelN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMSAmerican Shared Hospital Services106.51 million4.96 millionNot OptionableBOLTBolt Biotherapeutics901.92 million1.33 millionNot OptionableTNTartisan NickelN/AN/AN/ANot OptionableTN, AMS, and BOLT HeadlinesRecent News About These CompaniesTartisan Nickel Completes Phase 2 Construction on the Kenbridge Nickel All-Season Access Road, Receives Critical Realignment Road PermitJune 19, 2025 | juniorminingnetwork.comTartisan Nickel Corp. Completes Phase 2 Construction on the Kenbridge Nickel All-Season Access Road, Receives Critical Realignment Road PermitJune 19, 2025 | finance.yahoo.comTartisan Nickel Corp. Advances Kenbridge Project with New Exploration InitiativesMay 1, 2025 | tipranks.comTartisan Nickel Completes Key Road Access for Kenbridge ProjectApril 22, 2025 | tipranks.comTartisan Nickel Completes Phase 1 Construction on the Kenbridge Nickel Project All-Season Access RoadApril 22, 2025 | juniorminingnetwork.comTartisan Nickel Corp. Completes Phase 1 Construction on the Kenbridge Nickel Project All-Season Access RoadApril 22, 2025 | finance.yahoo.comTartisan Nickel Completes Initial Data Interpretation from the Airborne EM26 Survey, Turtle Pond Knight Danger Nickel-Copper-Platinum ProjectFebruary 27, 2025 | juniorminingnetwork.comTartisan Nickel Corp. Completes Initial Data Interpretation from the Airborne EM26 Survey, Turtle Pond Knight Danger Nickel-Copper-Platinum ProjectFebruary 27, 2025 | finance.yahoo.comTartisan Nickel Corp. Unveils Promising Survey Results at Turtle Pond ProjectFebruary 27, 2025 | tipranks.comTSX Penny Stock Highlights For December 2024December 31, 2024 | finance.yahoo.comTartisan Nickel Corp. Closes $1,500,000 Flow-Through Financing at $0.24 per Share with a Thirteen Month Escrow PeriodNovember 25, 2024 | finance.yahoo.comTartisan Nickel Secures $1.5M for Exploration ProjectsNovember 25, 2024 | tipranks.comView Interior Photos of the 2025 Porsche Panamera Turbo S E-HybridOctober 22, 2024 | ca.finance.yahoo.comTartisan Nickel Corp. Provides Kenbridge Nickel Project Road Work UpdateOctober 22, 2024 | finance.yahoo.comInvestorNewsBreaks – Tartisan Nickel Corp. (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA) Names Seasoned Veteran as New DirectorAugust 28, 2024 | msn.comTennessee State Tax GuideAugust 28, 2024 | kiplinger.comKTartisan Nickel Corp. Appoints Carl J. McGill DirectorAugust 28, 2024 | finance.yahoo.comTartisan Nickel Corp. (TTSRF)July 31, 2024 | finance.yahoo.comTexans training camp: Jalen Pitre embracing new role in the nickelJuly 24, 2024 | msn.comTennessee lawmakers pass bill allowing teachers, school staff to carry concealed handgunsMay 17, 2024 | usatoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIntel's Silent Comeback: 3 Pillars the Market Is OverlookingBy Jeffrey Neal Johnson | September 12, 2025Williams-Sonoma Q2 Results Prove Its Buy-and-Hold QualityBy Thomas Hughes | August 27, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 20253 Reasons Gartner Could Be the Best Buy of Q3By Sam Quirke | August 29, 2025Improving Fundamentals Drive New Buybacks for 3 Strong PerformersBy Leo Miller | August 29, 2025TN, AMS, and BOLT Company DescriptionsAmerican Shared Hospital Services NYSEAMERICAN:AMS$2.44 -0.01 (-0.41%) Closing price 04:10 PM EasternExtended Trading$2.43 -0.01 (-0.41%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.American Shared Hospital Services provides stereotactic radiosurgery and advanced radiation therapy equipment. It operates in two segments, Medical Equipment Leasing, and Retail. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units; and leases medical equipment. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. The company markets its solutions to cancer treatment centers, hospitals, and cancer networks worldwide. American Shared Hospital Services was founded in 1980 and is based in San Francisco, California.Bolt Biotherapeutics NASDAQ:BOLT$5.55 +0.21 (+3.93%) Closing price 04:00 PM EasternExtended Trading$5.54 0.00 (-0.09%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Tartisan Nickel CNSX:TNTartisan Nickel Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Peru. It owns 100% interests in the Kenbridge nickel project located in Ontario, Canada; the Don Pancho polymetallic zinc-lead-silver-manganese project situated in the Province of Huaral, Peru; the Sill Lake silver-lead project located in the Sault Ste. Marie Mining District of Ontario; and the Ichuna copper-silver project located in the Department of Moquegua in Southern Peru. The company was formerly known as Tartisan Resources Corp. and changed its name to Tartisan Nickel Corp. in February 2018. Tartisan Nickel Corp. was incorporated in 2008 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
